# Efficacy of a One-a-Day L. Reuteri NCIMB 30242 Probiotic Supplement Capsule

Study · id `cardio:ct-nct01630668` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01630668](<https://clinicaltrials.gov/study/NCT01630668>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01630668

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.

## Technical summary

Registry record NCT01630668. Randomized; double masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2013-12 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 150 participants (enrolled count; ClinicalTrials.gov record NCT01630668, source copy `cardio:ctgov-nct01630668-2014-06-26`, retrieved 2026-10-31)
- Start date: 2012-08 (registry gives no type) (ClinicalTrials.gov record NCT01630668, source copy `cardio:ctgov-nct01630668-2014-06-26`, retrieved 2026-10-31)
- Primary completion: 2013-12 (actual) (ClinicalTrials.gov record NCT01630668, source copy `cardio:ctgov-nct01630668-2014-06-26`, retrieved 2026-10-31)
- Completion: 2014-06 (actual) (ClinicalTrials.gov record NCT01630668, source copy `cardio:ctgov-nct01630668-2014-06-26`, retrieved 2026-10-31)
- Countries: Canada (ClinicalTrials.gov record NCT01630668, source copy `cardio:ctgov-nct01630668-2014-06-26`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01630668-2014-06-26`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy of a One-a-Day L. Reuteri NCIMB 30242 Probiotic Supplement Capsule
- Condition: Hypercholesterolemia
- Intervention (Dietary supplement): One-a-Day L. reuteri NCIMB 30242 supplement capsule
- Intervention (Dietary supplement): One-a-Day placebo capsule
- Lead sponsor: Micropharma Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)

## Provenance

Content hash: c884cf25b943cb2d77e8d9cfd3b1e6f9ef3c516d4de3af3a69feab5bf8c0b344
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
